Moreover, the PROBASE study suggested that risk-adapted PSA screening can potentially inhibit PCa progression to metastatic disease, and that the prevalence of screen-detected invasive PCa was very low in 45-year-old men [4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.